CTM Metformin Ia is a biotechnological solution based on mesenchymal stem cells pretreated with metformin, designed to promote the repair of joint tissues and support regenerative therapies in orthopedics. Its intra-articular application helps modulate inflammation, stimulate cellular processes, and promote the regeneration of cartilage and connective tissues.
Mesenchymal stem cells play a key role in the repair of joint tissues through mechanisms that include immunological modulation, prevention of apoptosis, and stimulation of cellular regeneration. These properties help improve joint functionality and support the recovery of damaged structures.
Mesenchymal stem cells play a key role in the repair of joint tissues through mechanisms that include immunological modulation, prevention of apoptosis, and stimulation of cellular regeneration. These properties help improve joint functionality and support the recovery of damaged structures.
Pretreatment with metformin acts on the Oct-1 pathway, increasing the expression of Glut2 and Glut4 transporters in bone tissues, promoting energy metabolism and stimulating the osteogenic differentiation of mesenchymal stem cells.
Mesenchymal stem cells administered through the intra-articular route migrate toward the injured tissue and actively participate in regenerative processes through the secretion of anti-inflammatory molecules, immunological stimulation, and cellular proliferation in cartilage and connective tissues.
Designed for healthcare professionals who integrate advanced regenerative therapies into the treatment of joint injuries and orthopedic conditions.
